+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Immuno-Oncology - Global Market Trajectory & Analytics

  • ID: 5309486
  • Report
  • April 2021
  • Region: Global
  • 157 pages
  • Global Industry Analysts, Inc
Global Immuno-Oncology Market to Reach $163.1 Billion by 2027

Amid the COVID-19 crisis, the global market for Immuno-Oncology estimated at US$63.9 Billion in the year 2020, is projected to reach a revised size of US$163.1 Billion by 2027, growing at a CAGR of 14.3% over the analysis period 2020-2027. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is projected to record a 14.2% CAGR and reach US$143.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immune System Modulators segment is readjusted to a revised 15% CAGR for the next 7-year period.



The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 13.8% CAGR

The Immuno-Oncology market in the U.S. is estimated at US$18.9 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$28.4 Billion by the year 2027 trailing a CAGR of 13.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.7% and 12.3% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.

Cancer Vaccines Segment to Record 15.6% CAGR

In the global Cancer Vaccines segment, USA, Canada, Japan, China and Europe will drive the 15.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion in the year 2020 will reach a projected size of US$4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$19.5 Billion by the year 2027.

Select Competitors (Total 47 Featured):
  • AbbVie, Inc.
  • Aduro BioTech, Inc.
  • Amgen, Inc.
  • AstraZeneca PLC
  • Bavarian Nordic A/S
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Celldex Therapeutics, Inc.
  • Eli Lilly and Company
  • EMD Serono, Inc.
  • F. Hoffmann-La Roche AG
  • Galena Biopharma, Inc.
  • Gilead Sciences, Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Incyte Corporation
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Novartis International AG
  • Pfizer, Inc.
  • Prometheus Laboratories, Inc.
  • Sanofi SA
Note: Product cover images may vary from those shown
I. METHODOLOGY

II. EXECUTIVE SUMMARY
  • Influencer Market Insights
  • Impact of Covid-19 and a Looming Global Recession
  • Table 1: World Current & Future Analysis for Immuno-Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 2: World 7-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027
  • Table 3: World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 4: World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 5: World Current & Future Analysis for Immune System Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 6: World 7-Year Perspective for Immune System Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 7: World Current & Future Analysis for Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 8: World 7-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 9: World Current & Future Analysis for Oncolytic Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 10: World 7-Year Perspective for Oncolytic Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 11: World Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 12: World 7-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 13: World Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 14: World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 15: World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 16: World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 17: World Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 18: World 7-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 19: World Current & Future Analysis for Renal Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 20: World 7-Year Perspective for Renal Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 21: World Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 22: World 7-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
  • Table 23: World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 24: World 7-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027
III. MARKET ANALYSIS
  • Table 25: USA Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 26: USA 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 27: USA Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 28: USA 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 29: Canada Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 30: Canada 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 31: Canada Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 32: Canada 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 33: Japan Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 34: Japan 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 35: Japan Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 36: Japan 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 37: China Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 38: China 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 39: China Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 40: China 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 41: Europe Current & Future Analysis for Immuno-Oncology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
  • Table 42: Europe 7-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027
  • Table 43: Europe Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 44: Europe 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 45: Europe Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 46: Europe 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 47: France Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 48: France 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 49: France Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 50: France 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 51: Germany Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 52: Germany 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 53: Germany Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 54: Germany 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 55: Italy Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 56: Italy 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 57: Italy Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 58: Italy 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 59: UK Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 60: UK 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 61: UK Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 62: UK 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 63: Rest of Europe Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 64: Rest of Europe 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 65: Rest of Europe Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 66: Rest of Europe 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 67: Asia-Pacific Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 68: Asia-Pacific 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 69: Asia-Pacific Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 70: Asia-Pacific 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
  • Table 71: Rest of World Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 72: Rest of World 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027
  • Table 73: Rest of World Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
  • Table 74: Rest of World 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027
IV. COMPETITION
  • Total Companies Profiled: 47
Note: Product cover images may vary from those shown
Adroll
adroll